Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Invesco Preferred ETF (PGX) Price & Performance

Neurocrine Biosciences IncTrade
Invesco Preferred ETFTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Invesco Preferred ETF — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while Invesco Preferred ETF trades at $10.64. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.

NBIXPGX
Market Cap
$16.76B
Sector
Health
52-Week High
$185.50$11.87
52-Week Low
$123.10$10.65
Enterprise Value
$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Invesco Preferred ETF

PGX trades at $10.72 with a slight 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $11 across multiple levels. Recent corporate actions include scheduled dividends for mid-2026, but current financial ratios and income statements lack available data for fundamental assessment.

The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunities hinge on future financial disclosures and business developments, while risks include technical downtrend continuation and potential volatility from unresolved financial metrics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Invesco Preferred ETF

The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.

Read more on PGX